Cargando…

Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection

Passive immunization with broadly neutralizing antibodies (bNAbs) of HIV-1 appears a promising strategy for eliciting long-term HIV-1 remission. When administered concomitantly with the cessation of antiretroviral therapy (ART) to patients with established viremic control, bNAb therapy is expected t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saha, Ananya, Dixit, Narendra M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728175/ https://www.ncbi.nlm.nih.gov/pubmed/33253162 http://dx.doi.org/10.1371/journal.pcbi.1008434

Ejemplares similares

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Selection of Peptide Mimics of HIV-1 Epitope Recognized by Neutralizing Antibody VRC01
por: Chikaev, Anton N., et al.
Publicado: (2015)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
por: Magaret, Craig A., et al.
Publicado: (2019)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
por: Cale, Evan M., et al.
Publicado: (2020)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
por: Knudsen, Maria L., et al.
Publicado: (2022)

Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
por: Caniels, Tom G., et al.
Publicado: (2023)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
por: Cardozo-Ojeda, E. Fabian, et al.
Publicado: (2021)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021)

The reservoir of latent HIV
por: Chen, Jing, et al.
Publicado: (2022)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Deep sequencing with longitudinal sampling of a VRC01-like-antibody response in a chronically infected individual
por: Zhang, Z, et al.
Publicado: (2012)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies
por: Otsuka, Yuka, et al.
Publicado: (2018)

A systematic analysis of the expression of the anti-HIV VRC01 antibody in Pichia pastoris through signal peptide optimization
por: Aw, Rochelle, et al.
Publicado: (2018)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris
por: Aw, Rochelle, et al.
Publicado: (2017)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
por: Kwon, Young D., et al.
Publicado: (2021)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
por: Kwon, Young D., et al.
Publicado: (2023)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
por: Guo, D, et al.
Publicado: (2012)

Characterization of VRC01, a potent and broadly neutralizing anti‐HIV mAb, produced in transiently and stably transformed tobacco
por: Teh, Audrey Y‐H., et al.
Publicado: (2013)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
por: Seydoux, Emilie, et al.
Publicado: (2021)

First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
por: Beckford-Vera, Denis R., et al.
Publicado: (2022)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

Heterogeneity of HIV-1 latent reservoirs
por: Zhao, Jia-Cong, et al.
Publicado: (2020)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
por: Bonsignori, Mattia, et al.
Publicado: (2018)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
por: Borst, Andrew J, et al.
Publicado: (2018)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
por: Calenda, Giulia, et al.
Publicado: (2019)

Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir
por: Suryawanshi, Poonam, et al.
Publicado: (2021)

HIV-1 latent reservoir: size matters
por: Hodel, Flavia, et al.
Publicado: (2016)

Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan
por: Umotoy, Jeffrey, et al.
Publicado: (2019)

B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models
por: Huang, Deli, et al.
Publicado: (2020)

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells
por: Lee, Jeong Hyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_05ui7b45l6lrvno9sqplgq9tfc